Clinical Applications of Polymeric Micelle Carrier Systems in Chemotherapy and Image Diagnosis of Solid Tumors

Journal of Experimental and Clinical Medicine

Volumn 3, Issue 4, 2011, Pages 151-158

  Yokoyama, Masayuki ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Drug carriers; Image diagnosis; Polymeric micelles; Solid tumors

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; COPOLYMER; DOXORUBICIN; DRUG CARRIER; GENEXOL PM; NK 105; NK 911; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; SP 1049C; UNCLASSIFIED DRUG;

ANGIOGENESIS; BIOACCUMULATION; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; HYDROPHOBICITY; LIVER METABOLISM; LIVER TOXICITY; MACROMOLECULE; MICELLE; MOLECULAR STABILITY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PASSIVE TRANSPORT; POLYMERIC MICELLE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SOLUBILITY; TUMOR VASCULARIZATION;

EID: 80053051929     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2011.06.002     Document Type: Review

References (79)

1. Aliabadi M., Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 2006, 3:139-162.
2. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003, 92:1343-1355.
3. Yokoyama M. Block Copolymers as drug Carriers. Crit Rev Ther Drug Carrier Syst 1992, 9:213-248.
4. Yokoyama M. Polymeric micelles for the targeting of hydrophobic drugs. Drug and pharmaceutical sciences vol. 148 polymeric drug delivery systems 2005, 533-575. Taylor & Francis, Boca Raton. G.S. Kwon (Ed.).
5. Yokoyama M. Polymeric micelles as nano-sized drug carrier systems. Nanoparticles for pharmaceutical applications 2007, 63-72. American Scientific Publishers, Stevenson Ranch. Y. Tabata (Ed.).
6. Yokoyama M. Polymeric micelles as a novel drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv 2010, 7:145-158.
7. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6:714-729.
8. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27:2569-2589.
9. Tuzar Z., Kratochvil P. Block and graft copolymer micelles in solution. Adv Colloid Interface Sci 1976, 6:201-232.
10. Calderara F., Hruska Z., Hurtrez G., Lerch J.P., Nugay T., Riess G. Investigation of polystyrene-poly(ethylene oxide) block copolymer micelle formation in organic and aqueous solutions by nonradiative energy transfer experiments. Macromolecules 1994, 27:1210-1215.
11. Wang Y., Kausch C.M., Chun M., Quirk R.P., Mattice W.L. Exchange of chains between micelles of labeled polystyrene-block-poly(oxyethylene) as monitored by nonradiative singlet energy transfer. Macromolecules 1995, 28:904-911.
12. Wilhelm M., Zhao C.L., Wang Y., Xu R., Winnik R.A. Poly(styrene-ethylene oxide) block copolymer micelle formation in water: a fluorescence probe study. Macromolecules 1991, 24:1033-1040.
13. Desjardins A., Eisenberg A. Colloidal properties of block ionomers. I. Characterization of reverse micelles of styrene-b-metal methacrylate diblocks by size-exclusion chromatography. Macromolecules 1991, 24:5779-5790.
14. Yokoyama M., Kwon G.S., Kataoka K. Preparation of micelle-forming polymer-drug conjugates. Bioconjugate Chem 1992, 3:295-301.
15. Hoes C.J.T., Potman W., Feijen J. Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin. J Control Release 1985, 2:205-213.
16. Duncan R., Kopeckova-Rejmanova P., Kopecek J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers I. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 1987, 55:165-174.
17. Endo N., Umemoto N., Hara T. A novel covalent modification of antibodies at their amino groups with retention of antigen-binding activity. J Immunol Methods 1987, 104:253-258.
18. Zunino F., Pratesi G., Micheloni A. Poly(carboxylic acid) polymers as carriers for anthracyclines. J Control Release 1989, 10:65-73.
19. Harada A., Kataoka K. Novel polyion complex micelles entrapping enzyme molecules in the core: Preparation of narrowly-distributed micelles from lysozyme and poly(ethylene glycol)-poly(aspartic acid) block copolymer in aqueous medium. Macromolecules 1998, 31:288-294.
20. Kataoka K., Togawa H., Harada A., Yasugi K., Matsumoto T., Katayose S. Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolecules 1996, 29:8556-8557.
21. Yokoyama M., Okano T., Sakurai Y., Suwa S., Kataoka K. Introduction of cisplatin into polymeric micelle. J Control Release 1996, 39:351-356.
22. Nishiyama N., Yokoyama M., Aoyagi T., Okano T., Sakurai Y., Kataoka K. Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum (II) and poly(ethylene glycol)-poly(α,β-aspartic acid) block copolymer in an aqueous medium. Langmuir 1999, 15:377-383.
23. Nishiyama N., Okazaki S., Cabral H., Miyamoto M., Kato Y., Sugiyama Y., Nishio K., et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003, 63:8977-8983.
24. Nakamura E., Makino K., Okano T., Yamamoto T., Yokoyama M. A polymeric micelle MRI contrast agent with changeable relaxivity. J Control Release 2006, 114:325-333.
25. Shiraishi K., Kawano K., Minowa T., Maitani Y., Yokoyama M. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. J Control Release 2009, 136:14-20.
26. Shiraishi K., Kawano K., Maitani Y., Yokoyama M. Synthesis of poly(ethylene glycol)-b-poly(L-lysine) block copolymers having Gd-DOTA as MRI contrast agent and their polymeric micelle formation by polyion complexation. J Control Release 2010, 148:160-167.
27. Yokoyama M., Okano T. Targetable drug carriers: Present status and a future perspective. Adv Drug Deliv Rev 1996, 21:77-80.
28. Sugiyama Y. Importance of pharmacokinetic considerations in the development of drug delivery systems. Adv Drug Deliv Rev 1996, 19:333-334.
29. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
30. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992, 3:351-361.
31. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
32. Litzinger D.C., Buiting A.M.J., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994, 1190:99-107.
33. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic consideration on biodistribution. Pharm Res 1996, 13:820-831.
34. Illum L., Davis S.S., Miller R.H., Mak E., West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer - Poloxamine 908. Life Sci 1987, 40:367-374.
35. Yokoyama M., Inoue S., Kataoka K., Yui N., Sakurai Y. Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent. Makromolekulare Chemie Rapid Communications 1987, 8:431-435.
36. Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., Inoue S. Characterization and anti-cancer activity of micelle-forming polymeric anti-cancer drug, adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res 1990, 50:1693-1700.
37. Yokoyama M., Okano T., Sakurai Y., Ekimoto H., Shibazaki C., Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric drug and its extremely long circulation in blood. Cancer Res 1991, 51:3229-3236.
38. Kwon G.S., Suwa S., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J Control Release 1994, 29:17-23.
39. Yokoyama M., Okano T., Sakurai Y., Fukushima S., Okamoto K., Kataoka K. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Target 1999, 7:171-186.
40. Lammers T., Kiessling F., Hennink W.E., Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010, 7:1899-1912.
41. Lu Z.R., Ye F., Vaidya A. Polymer platforms for drug delivery and biomedical imaging. J Control Release 2007, 122:269-277.
42. Bogdanov A., Wright S.C., Marecos E.M., Bogdanova A., Martin C., Petherick P., Weissleder R. A long-circulating co-polymer in "passive targeting" to solid tumors. J Drug Target 1997, 4:321-330.
43. Gupta H., Weissleder R. Targeted contrast agents in MR imaging. Magn Reson Imaging Clin N Am 1996, 4:171-184.
44. Bogdanov A.A., Lewin M., Weissleder R. Approaches and agents for imaging the vascular system. Adv Drug Deliv Rev 1999, 37:279-293.
45. Lebdusková P., Kotek J., Hermann P., Vander Elst L., Muller R.N., Lukes I., Peters J.A. A gadolinium(III) complex of a carboxylic-phosphorus acid derivative of diethylenetriamine covalently bound to inulin, a potential macromolecular MRI contrast agent. Bioconjug Chem 2004, 15:881-889.
46. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99:2293-2352.
47. Pathak A.P., Gimi B., Glunde K., Ackerstaff E., Artemov D., Bhujwalla Z.M. Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 2004, 386:3-60.
48. Nagy J.A., Benjamin L., Zeng H., Dvorak A.M., Dvorak H.F. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
49. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988, 133:95-109.
50. Dvorak H.F., Brown L.F., Detmar M., DvorakReview A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
51. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
52. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
53. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153.
54. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 2001, 18:1042-1048.
55. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995, 31A:766-770.
56. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009, 100:572-579.
57. Matsumura Y. Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol 2008, 38:793-802.
58. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 2008, 60:899-914.
59. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004, 91:1775-1781.
60. Hamaguchi T., Kato K., Yasui H., Morizane C., Ikeda M., Ueno H., Muro K., et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007, 97:170-176.
61. Uchino H., Matsumura Y., Negishi T., Koizumi F., Hayashi T., Honda T., Nishiyama N., et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005, 93:678-687.
62. Negishi T., Koizumi F., Uchino H., Kuroda J., Kawaguchi T., Naito S., Matsumura Y. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer 2006, 95:601-606.
63. Hamaguchi T., Matsumura Y., Suzuki M., Shimizu K., Goda R., Nakamura I., Nakatomi I., et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005, 92:1240-1246.
64. Cabral H., Nishiyama N., Kataoka K. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release 2007, 121:146-155.
65. Koizumi F., Kitagawa M., Negishi T., Onda T., Matsumoto S., Hamaguchi T., Matsumura Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006, 66:10048-10056.
66. Kim D.W., Kim S.Y., Heo D.S., Kim H.K., Kim S.W., Shin S.W., Kim J.S., et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18:2009-2014.
67. Lee K.S., Chung H.C., Ro J., Im S.A., Park Y.H., Kim C.S., Kim S.B., et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
68. Sharma A.K., Zhang L., Li S., Kelly D.L., Alakhov V.Y., Batrakova E.V., Kabanov A.V., et al. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J Control Release 2008, 131:220-227.
69. Danson S., Alakhov V., Ranson M., Ferry D., Margison J., Kerr D., Jowle D., et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004, 90:2085-2091.
70. Chansri N., Kawakami S., Yokoyama M., Yamamoto T., Charoensit P., Hashida M. Anti-tumor effect of all-trans retinoic acid loaded polymeric micelles in solid tumor bearing mice. Pharm Res 2008, 25:428-434.
71. Okuda T., Kawakami S., Yokoyama M., Yamamoto T., Yamashita F., Hashida M. Block copolymer design for stable encapsulation of N-(4-hydroxyphenyl)retinamide into polymeric micelles in mice. Int J Pharm (Note) 2008, 357:318-322.
72. Okuda T., Kawakami S., Higuchi Y., Satoh T., Oka Y., Yokoyama M., Yamashita F., et al. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharmaceutics 2009, 373:100-106.
73. Satoh T., Higuchi Y., Kawakami S., Hashida M., Kagechika H., Shudo K., Yokoyama M. Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids' release control. J Control Release 2009, 136:187-195.
74. Yokosawa M., Sonoda Y., Sugiyama S., Saito R., Yamashita Y., Nishihara M., Satoh T., et al. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. Tohoku J Exp Med 2010, 221:257-264.
75. Inoue T., Yamashita Y., Nishihara M., Sugiyama S., Sonoda, Kumabe T., Yokoyama M., et al. Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro-Oncology 2009, 11:151-157.
76. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., Fujii T., et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 2007, 104:3460-3465.
77. Minowa T., Kawano K., Kuribayashi H., Shiraishi K., Sugino T., Hattori Y., Yokoyama M., et al. Increase in tumor permeability following TGF-b type I receptor inhibitor treatment observed by dynamic contrast-enhanced MRI. Br J Cancer 2009, 101:1884-1890.
78. Seki T., Fang J., Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 2009, 100:2426-2430.
79. Hori K., Nishihara M., Yokoyama M. The combretastatin derivative cderiv, a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors. J Pharm Sci 2010, 99:2914-2925.